The FDA approved Sanofi's Infilbray (venglustat) on November 19, 2026, making it the first therapy cleared in the US for the neurological symptoms of Gaucher disease type 3. The approval covers adults and children weighing at least 15 kg. Infilbray is a brain-penetrating small molecule; its label warns of suicidal thoughts risk. Sanofi's existing Gaucher drugs Cerezyme and Cerdelga topped €1B in 2025 sales.
Infilbray FDA approval
- ▪The Infilbray label notes that the drug may increase the risk of suicidal thoughts and behavior
- ▪Infilbray is a small molecule designed to block an enzyme key to the synthesis of glycosphingolipids
- ▪Infilbray's FDA approval covers treatment of Gaucher disease type 3 in adults and in children who weigh at least 15 kg (about 33 pounds)
- ▪FDA approved Infilbray (venglustat), making it the first approved therapy for the neurological symptoms of Gaucher disease
Gaucher type 3 disease
- ▪Dr. Pramod Mistry is the director of the Yale Lysosomal Disease Center and Gaucher Disease Treatment Center
- ▪In Gaucher disease, mutations in the GBA1 gene lead to deficiency of the enzyme glucocerebrosidase, causing fatty molecules called glycosphingolipids to build up in organs of the body
- ▪In Gaucher disease type 3, fatty accumulation in the central nervous system leads to dementia and loss of muscle control
- ▪Patients with Gaucher disease type 3 also experience organ problems throughout the body, such as liver and spleen enlargement
Clinical trial results
- ▪At one year, Infilbray showed statistically significant improvement on a test assessing multiple neurological measures in the Phase 3 trial
- ▪Venglustat did not meet the goals of a Phase 3 test in Fabry disease, another rare enzyme deficiency, results reported prior to November 19, 2026
- ▪The most common adverse effects reported in the Infilbray Phase 3 trial included diarrhea, an enlarged spleen, and nausea
- ▪In the Infilbray Phase 3 trial, daily oral doses of Infilbray were compared to intravenous enzyme replacement therapy administered every two weeks
- ▪The Phase 3 trial supporting Infilbray's FDA approval enrolled adults and pediatric patients age 12 and older with Gaucher type 3 who had achieved systemic disease stabilization with prior enzyme replacement therapy
Sanofi Gaucher franchise
- ▪For 2025, Sanofi reported that Cerezyme and Cerdelga together generated more than €1 billion (about $1.1 billion) in global sales
- ▪Sanofi sells Cerdelga, an oral drug approved in 2014 for treating adults with Gaucher type 1
- ▪Sanofi sells Cerezyme, an enzyme replacement therapy for Gaucher disease, which competes with enzyme replacement therapies from Takeda Pharmaceutical and Pfizer; all three products are approved for Gaucher type 1
- ▪Both Cerezyme and Cerdelga originated from Genzyme, which Sanofi acquired in 2011
Story comments
Loading comments…